Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 7, 2013
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its infant formula division has gained FDA clearance to manufacture three new infant formula...
-
Jan 2, 2013
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the J.P. Morgan 31st...
-
Dec 28, 2012-- Solidifies Perrigo's leadership position in topical foam-based generic prescription pharmaceuticals
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek...
-
Dec 4, 2012
The Perrigo Company (Nasdaq: PRGO;TASE) today announced the appointment of Douglas Boothe as Executive Vice President and General Manager, Perrigo...
-
Nov 28, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev® (acetaminophen)...
-
Nov 27, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, Cobrek Pharmaceuticals, Inc., received final approval from the U.S. Food and...
-
Nov 13, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Credit Suisse...
-
Nov 13, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote® (acetylcysteine)...
-
Nov 7, 2012- Fiscal first quarter adjusted net income increased 16% to a record $119 million, or $1.27 per diluted share, inclusive of an $0.08 tax benefit.
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its first quarter ended September 29, 2012. (Logo:...
-
Nov 6, 2012
The Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors has appointed Jacqualyn A. Fouse, Ph.D. as a new director of the...
-
Nov 6, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.09 per share, payable on December...
-
Oct 23, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its first quarter fiscal year 2013 on Wednesday,...
-
Oct 16, 2012
The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for...
-
Oct 10, 2012
The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its...
-
Oct 1, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has closed the acquisition of Sergeant's Pet Care Products, Inc. (Sergeant's), a...
-
Sep 18, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer Judy Brown will present at the...
-
Sep 13, 2012-- Sergeant's Pet Care Products, Inc., a privately-held OTC animal health company, expands Perrigo's portfolio to include a new adjacent product category, companion animal healthcare
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of...
-
Sep 7, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Morgan Stanley Global...
-
Sep 6, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration...
-
Aug 27, 2012
Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial launch of a major new store brand...
-
Aug 16, 2012- Full-year revenue from continuing operations increased $418 million, or 15%, to a record $3.2 billion.
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012. (Logo:...
-
Aug 15, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on September...
-
Aug 9, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Aug 8, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Aug 2, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its fourth quarter and fiscal year 2012 on Thursday,...
-
Jun 27, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Jun 11, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Clobetasol propionate...
-
Jun 8, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer Judy Brown will present at the...
-
Jun 6, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 30, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval to Tris Pharma for its...
-
May 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and Chief Executive Officer, Joseph C. Papa, will present at the...
-
May 22, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 18, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 15, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer, Judy L. Brown, will present at...
-
May 8, 2012-- Fiscal third quarter revenue from continuing operations increased $86 million, or 13%, to $778 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 31, 2012. (Logo:...
-
May 3, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on June 19,...
-
Apr 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its third quarter fiscal 2012 on Tuesday, May 8, 2012...
-
Apr 12, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version...
-
Mar 21, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic...
-
Mar 13, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Chairman, President and CEO Joseph C. Papa will present at the Barlcays Capital Global...
-
Mar 1, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated market launch and made its first shipments of minoxidil 5% foam to its retail and...
-
Feb 28, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced its Chairman & CEO Joseph Papa will present at the RBC Capital Markets' Healthcare Conference on...
-
Feb 14, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to...
-
Feb 8, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown will present at the Leerink Swann 2012 Global Healthcare Conference on...
-
Feb 7, 2012- Fiscal second quarter revenue from continuing operations increased $121 million, or 17%, to a record $838 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its second quarter and six months ended December 31, 2011. Perrigo's Chairman and CEO...
-
Feb 2, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on March 20,...
-
Jan 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2012 on Tuesday,...
-
Jan 23, 2012
Perrigo Company (Nasdaq: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application...
-
Jan 12, 2012
Perrigo Company (NASDAQ: PRGO; TASE) announced today that the United States District Court for the Western District of Michigan has granted summary...
-
Jan 9, 2012- CanAm Care expands Perrigo's diabetes care product offering
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm...
-
Jan 6, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 30th Annual J.P. Morgan Healthcare...
-
Dec 27, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Nov 28, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its...
-
Nov 15, 2011
Perrigo Company (NASDAQ: PRGO; TASE) today announced it received Food and Drug Administration (FDA) clearance to market and distribute infant formula...
-
Nov 8, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has entered into Cooperation and License agreements with Brilite Nutritionals (Shanghai)...
-
Nov 7, 2011
Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine...
-
Nov 2, 2011
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for...
-
Nov 1, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl...
-
Oct 27, 2011-- Fiscal first quarter revenue from continuing operations increased $84 million, or 13%, to a record $725 million
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its first quarter ended September 24, 2011. Perrigo's Chairman and CEO Joseph...
-
Oct 26, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on December...
-
Oct 19, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has entered into a supply agreement with Founder Pharma Co., Ltd., a wholly owned...
-
Oct 18, 2011
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...
-
Oct 14, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2012 on Thursday, October 27,...
-
Oct 6, 2011
Perrigo Company (Nasdaq: PRGO;TASE) announced that it received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated...
-
Oct 4, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown and Senior Management will meet with analysts on Wednesday, October 5,...
-
Sep 23, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa and Senior Management will meet with analysts on...
-
Aug 30, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its...
-
Aug 16, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced it expects to issue $350 million of notes in its fiscal second quarter pursuant to its existing...
-
Aug 16, 2011-- Full-year revenue from continuing operations increased $487 million, or 21%, to a record $2.76 billion.
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 25, 2011. Perrigo's Chairman and CEO...
-
Aug 11, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...
-
Aug 2, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its fourth quarter fiscal 2011 on Tuesday, August 16 ,...
-
Jul 26, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has closed the acquisition of Paddock...
-
Jul 21, 2011
The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market...
-
Jun 29, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize the regulatory approvals necessary to complete the...
-
Jun 15, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories...
-
Jun 3, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Goldman Sachs 32nd Annual Global...
-
May 18, 2011
Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the...
-
May 16, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 10, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle all Hatch-Waxman litigation relating to fluticasone lotion brought by...
-
May 3, 2011-- Fiscal third quarter revenue from continuing operations increased $154 million, or 29%, to $692 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 26, 2011. Perrigo's Chairman and CEO Joseph C. Papa...
-
May 2, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Apr 28, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on June 14,...
-
Apr 21, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision...
-
Apr 19, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal 2011 on Tuesday, May 3, 2011...
-
Apr 13, 2011
Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to...
-
Apr 12, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of...
-
Mar 14, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Barclays Capital 2011 Global...
-
Mar 1, 2011
Perrigo (Nasdaq: PRGO;TASE) today announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the...
-
Feb 28, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi 2011 Global Health Care...
-
Feb 22, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for calcipotriene 0.005% and betamethasone...
-
Feb 21, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that it has begun selling OTC infant formula to Costco in Canada. The product will be sold under Costco's...
-
Feb 17, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that it has entered into an exclusive agreement with AgaMatrix, Inc. to sell and distribute blood glucose...
-
Feb 10, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by...
-
Feb 1, 2011
-- Fiscal second quarter revenue from continuing operations increased $135 million, or 23%, to $718 million -- Fiscal second quarter GAAP income from...
-
Jan 26, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on March...
-
Jan 20, 2011- Paddock Labs is a privately-held manufacturer and marketer of generic Rx pharmaceutical products
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock...
-
Jan 17, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its second quarter fiscal 2011 on Tuesday, February 1,...
-
Jan 7, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 29th Annual J.P. Morgan...
-
Dec 13, 2010
IR Global Rankings ("IRGR"), the most comprehensive technical ranking system for investor relations websites, corporate governance practices and...
-
Dec 10, 2010
JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 12/10/10 -- www.stockcall.com/ offers investors comprehensive research on the drug related products industry and has completed analytical research on...